CED's Biotech Forum

05/19/2010 05:30:00 PM - 05/19/2010 08:00:00 PM

Partnering with Big Pharma & The Campbell Alliance Dealmaker’s Intentions Survey

Date: May 19, 2009
Time: 5:30-8:00 p.m.
Location: North Carolina Biotechnology Center - Directions.

Moderator:

Gautam Aggarwal, Senior Practice Executive, Business Development Practice, Campbell Alliance

Panelists:

Leslie Boyd, Vice President, Scientific Licensing, GlaxoSmithKline

Beth Fordham-Meier, CLP Vice President, Licensing and Intellectual Property, Targacept, Inc.

Kinney Horn, Associate Director, Business Development, Genentech
Joseph E. Zack, Senior Vice President, Diagnostics, Metabolon

Panel Description:

The relationship between the pharmaceutical and biotechnology industries has never been more apparent. For pharma, patent expirations and depleted pipelines have forced companies to look externally for growth. For biotech, the lack of financing and an uncertain regulatory and reimbursement landscape threatens the progress of innovative new therapies. In this environment, the competition for unlicensed assets has never been more intense and top dealmakers will shape the future of the industry.

Getting inside the heads of business development professionals is not an easy task. Many resources available to business develop¬ment professionals provide retrospective data regarding deal activity in the pharmaceutical and biotech industry. These indispensable tools, including libraries of financing transac¬tions, deal databases, and royalty rate studies, provide timely information on deal activity as transactions are closed and announced. However, because deals often take more than a year to complete, these databases may not be good indicators of emerging strategies or the future deal environment. CED, in partnership with Campbell Alliance, is pleased to offer the only forward-looking measure of deal-making intentions in the pharma and biotech industries. During the first quarter of this year, Campbell Alliance surveyed more than 150 industry executives and business development professionals on their partnering expectations and intentions for 2010. The study goes far deeper than simply evaluating the current environment to identify the types of assets that will be in demand among in-licensors. The results of this study have also been linked with a review of the assets that are available for licensing, revealing supply and demand dynamics that are not always obvious, and that could have interesting implications for deal-making over the next 12 months or more. In this competitive landscape, many biotech companies will need to effectively differentiate between certain assets’ intrinsic values, and the value that is simply driven by asset scarcity in certain categories. The study goes beyond evaluating these trends at the therapeutic area level, and includes assessments that incorporate popular or new mechanisms of action, target market segments, and so on.

During this presentation and interactive panel discussion we will answer several key questions to provide insight into what will likely drive the industry’s partnering efforts moving forward, including:

What therapeutic areas, mechanisms of action, and target market segments are of most interest to large pharma and biotech companies, and how has that changed since last year?

Will over-crowding in some areas and scarcity in others lead to changes in deal-making priorities?

Given the competitive landscape described above, how are large pharma and biotech companies communicating their areas of interest and how must emerging companies shift their approach to outreach?

What stage of development is ideal for partnering, and how does that differ from the in-licensor’s and out-licensor’s perspectives?

What business models are being considered by biotech companies to compete and grow in this environment?

Attendees will receive a copy of the Campbell Alliance Dealmaker’s Intentions Survey

About CED's Biotech Forum

CED's Biotech Forum, in partnership with the North Carolina Biotechnology Center , explores industry topics and trends, features expert speakers and provides high quality networking. Join biotech entrepreneurs, industry executives, research leaders, services providers and investors quarterly at the North Carolina Biotechnology Center in Research Triangle Park, NC.

For more information, contact Dhruv Patel at dpatel@cednc.org / 919.549.7500 ext.118 or visit http://www.cednc.org/btforum